ACC 2022 | IVVE

This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure. 

ACC 2022

It included 5129 patients with cardiac failure randomized to receiving the flu vaccine annually for 3 years vs placebo. 

Primary end point included cardiovascular death, non-fatal AMI, and stroke. There were no significant differences between both groups. However, pneumonia rate and hospitalization were significantly lower in the group receiving the flu vaccine. 

When focusing on flu seasonal peak, the vaccinated group presented reduced primary end point (7.7% vs 9.4%; HR 0.82; 95% CI 0.68-0.99).

Conclusion

Annual vaccination against influenza in patients with cardiac failure reduces the risk of pneumonia and hospitalization at 3 years, though not major cardiovascular events, compared against placebo. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org .

Reference: Loeb M. A randomized controlled trial of influenza vaccine to prevent adverse vascular events (IVVE). Presented at: ACC 2022. April 3, 2022. Washington, DC.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
Next article

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...